1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited

0.13
EUR
+0.00
(+1.59%)
95.39MMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.32
1.76
1.6
1.58
1.71
1.92
2.06
2.07
2.15
2.09
1.79
2.38
2.44
- -
Basic EPS, GAAP
0.28
0.36
0.4
0.43
0.39
0.71
0.21
0.22
3.38
0.09
0.03
0.16
0.16
- -
Free Cash Flow per Basic Share
-0.08
0.17
-0.13
0.21
0.17
0.03
0.07
-0.24
-0.27
0.12
-0.08
0.06
0.17
- -
Dividend per Share
0.06
0.08
0.1
0.11
0.11
0.1
0.1
0.07
0.06
0.04
0.02
0.03
0.05
- -
Book Value per Share
1.46
1.72
2.5
2.71
3.05
3.73
3.91
3.66
4.19
3.27
3.46
2.81
3.47
3.35
Tangible Book Value per Share
1.06
1.25
1.9
1.76
2.05
2.51
2.72
2.21
2.61
1.52
1.63
0.87
1.18
1.59
Basic Weighted Avg Shares
530
543
576
589
591
592
592
588
589
589
589
589
589
589
Sales/Revenue/Turnover
697
955
922
930
1,009
1,138
1,219
1,217
1,266
1,233
1,053
1,400
1,436
- -
Operating Margin (%)
24.76
24.36
26.8
34.13
24.35
17.29
15.34
7.39
-13.69
6.21
-0.7
5.53
5.28
- -
Depreciation Expense
17
29
45
49
61
68
94
128
147
152
150
148
156
- -
Net Income, GAAP
150
193
229
252
233
418
126
129
1,987
51
17
93
92
- -
Effective Tax Rate (%)
15.38
18.13
16.12
17.76
21.23
12.68
48.45
41.41
0.48
32.46
35.2
30.07
30.55
- -
Profit Margin (%)
21.59
20.19
24.84
27.1
23.06
36.77
10.3
10.63
156.95
4.16
1.59
6.65
6.4
- -
Working Capital
370
422
560
525
442
328
533
295
41
2
8
13
39
2
LT Debt
- -
- -
1
1
1
1
13
8
92
80
75
70
87
84
Total Equity
852
999
1,517
1,635
1,797
2,238
2,477
2,115
2,391
1,843
1,961
1,549
1,900
1,897
Return on Invested Capital (%)
19.51
18.65
17.67
14.39
11.72
18.81
2.84
3.53
79.04
2.21
1.35
3.99
2.97
- -
Return on Capital (%)
19.81
20.37
18.76
16.36
14.47
21.12
7.61
7.45
81.89
2.62
1
6.46
7.06
- -
Return on Common Equity (%)
22
22.42
19.07
16.42
13.66
20.84
5.57
5.82
86.13
2.34
0.84
5.04
4.97
- -

Capital Structure

HKD

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
ST Debt
- -
84
118
LT Borrowings
- -
77
77
LT Finance Leases
- -
3
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
589
589
589
Market Capitalization
951
940
816

Working Capital

HKD

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
Total Current Assets
- -
652
707
Cash, Cash Equivalents & STI
- -
189
162
Accounts Receivable, Net
- -
111
120
Inventories
- -
249
325
Total Current Liabilities
- -
650
705
Payables & Accruals
- -
- -
- -
ST Debt
- -
84
118
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
-0.36%
22.68%
Free Cash Flow
-94.69%
-55%
194.16%
Net Income, GAAP
174.33%
345.62%
-1.25%
Sales/Revenue/Turnover
5.14%
4.47%
2.57%
Total Cash Common Dividend
0.02%
5.68%
56.67%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,053
2024
- -
- -
1,400
2025
- -
- -
1,436

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
0.16
2025
- -
- -
0.16

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.03
2025
- -
- -
0.05

Company Description

Company Profile APIChatGPT
CEO
Wanee Leelalertsuphakun
Full Time Employees
1,094
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 20E Hong Kong Hong Kong 164-8622
IPO Date
Jul 15, 2002
Website
leespharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Lee's Pharmaceutical Holdings Limited (HKEx: 950), founded in 1994 and headquartered in Sha Tin, Hong Kong, operates as an integrated research-driven biopharmaceutical company focused on the development, manufacturing, sales and marketing of proprietary, generic and licensed-in pharmaceutical products primarily in mainland China, Hong Kong, Macau and Taiwan. The company addresses key therapeutic areas including cardiovascular, infectious diseases, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, gynecology, urology and ophthalmology; its core offerings encompass self-developed products such as Fondaparinux Sodium Injection (Lichangqing), Nadroparin Calcium Injection (Litengjing), Treprostinil Injection (Ruineier), Socazolimab Injection, Adapalene and Clindamycin Hydrochloride Gel, Azilsartan Tablets and Sodium Phenylbutyrate Granules, alongside licensed-in products including INOmax (Nitric Oxide for Inhalation), Teglutik, Trittico, Natulan (Procarbazine Hydrochloride Capsules) and Adasuve (Loxapine for Inhalation). Manufacturing facilities located in Hefei, Anhui province and Guangzhou support production of injectables, lyophilized powders, gels, solid dosages, ophthalmic products and medical devices, with over 40 products in various development stages derived from internal R&D platforms like snake venom technology, low molecular weight heparin and water-based gel delivery systems, as well as partnerships with around 30 international firms from the United States, Europe and Japan. Recent developments include the launch of a new pre-filled production line with isolator technology at Zhaoke Pharmaceutical (Hefei) in June 2025 to enhance capacity for volume-based procurement products like Fondaparinux Sodium Injection and Nadroparin Calcium Injection; a strategic partnership with Shaohe Biotechnology in August 2025 to develop probiotic solutions for public health; commercial launches of in-house Adapalene and Clindamycin Hydrochloride Gel and in-licensed INOmax and INOmax DSIR Plus in 2024; and ongoing Phase I clinical trials for AU409 initiated in July 2024. The company maintains an investment in Zhaoke Ophthalmology Limited and reported a 5.5% revenue increase to HK$694.8 million in the first half of 2025, driven by expanded production and product portfolio growth.